No connection

Search Results

HQL vs SFST

HQL
Abrdn Life Sciences Investors
BULLISH
Price
$17.56
Market Cap
$534.0M
Sector
Financial Services
AI Confidence
75%
SFST
Southern First Bancshares, Inc.
NEUTRAL
Price
$56.68
Market Cap
$535.9M
Sector
Financial Services
AI Confidence
85%

Valuation

P/E Ratio
HQL
6.29
SFST
13.31
Forward P/E
HQL
--
SFST
8.61
P/B Ratio
HQL
1.01
SFST
1.26
P/S Ratio
HQL
275.47
SFST
4.4
EV/EBITDA
HQL
--
SFST
--

Profitability

Gross Margin
HQL
100.0%
SFST
0.0%
Operating Margin
HQL
-346.83%
SFST
41.16%
Profit Margin
HQL
4415.74%
SFST
28.7%
ROE
HQL
17.59%
SFST
9.76%
ROA
HQL
-0.43%
SFST
0.79%

Growth

Revenue Growth
HQL
-69.9%
SFST
26.2%
Earnings Growth
HQL
259.4%
SFST
83.1%

Financial Health

Debt/Equity
HQL
--
SFST
--
Current Ratio
HQL
0.73
SFST
--
Quick Ratio
HQL
0.71
SFST
--

Dividends

Dividend Yield
HQL
12.76%
SFST
--
Payout Ratio
HQL
65.23%
SFST
0.0%

AI Verdict

HQL BULLISH

HQL presents as a deep-value opportunity, anchored by a stable Piotroski F-Score of 6/9 and a significant valuation gap, with a current price of $17.56 trading well below its Graham Number ($33.01) and Intrinsic Value ($82.31). While the company exhibits severe operational anomalies—specifically a -69.90% revenue collapse and a deeply negative operating margin—the massive earnings growth and low P/E ratio (6.29) suggest the entity is benefiting from significant investment gains rather than core fee income. The high dividend yield of 12.76% is supported by a sustainable payout ratio, though the bearish technical trend (10/100) suggests a period of consolidation or price correction is underway.

Strengths
Extreme undervaluation relative to Graham Number ($33.01) and Intrinsic Value ($82.31)
Very low P/E ratio (6.29) compared to the sector average of 36.83
Strong dividend yield of 12.76% with a manageable payout ratio (65.23%)
Risks
Severe revenue decline (-69.90% YoY) indicating a collapse in core business growth
Poor operational efficiency with an operating margin of -346.83%
Liquidity risk evidenced by a current ratio of 0.73 (below 1.0)
SFST NEUTRAL

SFST presents a conflicting profile characterized by a weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial health. Despite this, the stock appears undervalued, trading at $56.68, which is below both its Graham Number ($65.59) and its growth-based Intrinsic Value ($125.67). While YoY earnings growth is exceptionally strong at 83.10%, this is offset by bearish insider selling and a very weak technical trend (10/100). The company is currently a high-growth value play with concerning underlying health metrics.

Strengths
Strong YoY earnings growth of 83.10%
Attractive valuation with a Forward P/E of 8.61
Trading below the defensive Graham Number of $65.59
Risks
Critical financial health warning with a Piotroski F-Score of 2/9
Bearish insider activity, including significant sales by the CEO
Very weak technical trend (10/100) suggesting downward momentum

Compare Another Pair

HQL vs SFST: Head-to-Head Comparison

This page compares Abrdn Life Sciences Investors (HQL) and Southern First Bancshares, Inc. (SFST) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile